朗迪Reneed品牌怎么样 申请店铺

我要投票 朗迪Reneed在补钙行业中的票数:537 更新时间:2025-07-31
朗迪Reneed是哪个国家的品牌?「朗迪Reneed」是 北京振东康远制药有限公司 旗下著名品牌。该品牌发源于北京市,由创始人李昆在2003-11-07期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力朗迪Reneed品牌出海!将品牌入驻外推网,定制朗迪Reneed品牌推广信息,可以显著提高朗迪Reneed产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

朗迪Reneed怎么样

钙营养补充剂品牌,主打维生素矿物质钙补充剂类药物,集研发、生产、销售于一体的集团化现代综合制药企业


北京振东康远制药有限公司始建于2003年10月,是国内较大的具有自主品牌的维生素矿物质钙补充剂类药物生产企业,是一家集研发、生产、销售于一体的集团化现代综合制药公司,是中国补钙药物的佼佼者和先锋。公司产品遍布全国,公司“朗迪”牌碳酸钙D3片(II)和碳酸钙D3颗粒已成为中国钙补充剂类药品市场的主流。公司2015年与上市公司振东集团山西振东制药股份有限公司强强联合,完成重大重组,实现了跨跃式发展。

公司于2009年进入中国钙制剂市场,旗下现有7家直属或控股的制药公司、2家直属药物研发公司及多家医药贸易公司,在30多个城市设立了办事机构,有数千家合作伙伴,累计总投资超过10亿元,全国有数千名员工为康远工作。

公司位于北京市昌平区西部约15公里的北京市昌平区流村工业园内,隶属中关村科技园昌平园。该厂区自2012年开始建造,总投资近亿元,按照新版欧盟GMP标准及中国GMP标准进行规划、设计和建设施工,配有国际前沿的制粒、干燥、混合、压片、包装等片剂、硬胶囊剂、颗粒剂生产线及软胶囊剂生产线,该项目已于2014年通过了BFDA组织的GMP认证,并获得片剂、硬胶囊剂、颗粒剂、软胶囊剂GMP证书。项目年生产能力近百亿片(粒、袋)。该项目的建成使康远制药一跃成为国内维生素矿物质钙补充剂类药物较大生产企业。

公司发展过程中始终以“构建国人健康骨骼”为已任,以“树民族工业品牌,为中国制药争光”为使命,为中国钙制剂的发展做出了较大的贡献,大大改善了亿万国人的生活质量。康远人负有共同的使命,遵循一致的价值观,始终秉承“济世安康、立勋鸿远”宗旨来服务社会、回报社会。目前公司年营业收入达数十亿元,年上缴税金数亿元。随着公司高速发展和对未来中国经济和全球钙制剂市场发展前景充分信心,北京振东康远制药正不断加快创新、运筹帷幄、酝酿百年规划,未来的康远终将成为一家拥有精良技术和设备、管理成熟的世界制药公司。


Beijing Zhendong Kangyuan Pharmaceutical Co., Ltd., a brand of calcium supplements, is a group modern comprehensive pharmaceutical enterprise integrating R & D, production and sales. It was founded in October 2003. It is a large domestic manufacturer of vitamin and mineral calcium supplements with its own brand, integrating R & D, production and sales Group modern comprehensive pharmaceutical company is the leader and pioneer of calcium supplements in China. The company's products are all over the country, and its "landi" brand calcium carbonate D3 tablets (II) and calcium carbonate D3 particles have become the mainstream of China's calcium supplements market. In 2015, the company and the listed company Zhendong Group Shanxi Zhendong Pharmaceutical Co., Ltd. jointly completed major restructuring and achieved a leap forward development. In 2009, the company entered the calcium preparation market in China. At present, it has 7 pharmaceutical companies directly under or controlled by the company, 2 pharmaceutical research and development companies directly under the company and many pharmaceutical trading companies. It has set up offices in more than 30 cities, thousands of partners, with a total investment of more than 1 billion yuan, and thousands of employees working for Kangyuan. The company is located in Liucun Industrial Park, Changping District, Beijing, about 15km away from the west of Changping District, Beijing. The plant has been constructed since 2012, with a total investment of nearly 100 million yuan. It is planned, designed and constructed in accordance with the new version of EU GMP standard and China GMP standard. It is equipped with internationally cutting-edge tablet, hard capsule, granule production line and soft capsule production line. The project has passed the GMP certification organized by bfda in 2014, and has obtained tablet GMP certificate of hard capsule, granule and soft capsule. The annual production capacity of the project is nearly 10 billion pieces (grain and bag). With the completion of the project, Kangyuan pharmaceutical has become a large domestic manufacturer of vitamin, mineral and calcium supplements. In the development process of the company, we always take "building healthy skeleton of Chinese people" as our responsibility, take "building national industrial brand, winning honor for Chinese pharmaceutical" as our mission, and have made great contribution to the development of Chinese calcium preparation, greatly improving the quality of life of hundreds of millions of Chinese people. Kangyuan people have a common mission, follow the same values, and always adhere to the tenet of "helping the world and health, and making contributions to Hongyuan" to serve and repay the society. At present, the company's annual operating revenue is billions of yuan, and the annual tax payment is hundreds of millions of yuan. With the rapid development of the company and full confidence in the future development of China's economy and the global calcium preparation market, Beijing Zhendong Kangyuan Pharmaceutical Co., Ltd. is constantly accelerating innovation, strategizing and brewing a hundred year plan. In the future, Kangyuan will eventually become a world pharmaceutical company with excellent technology and equipment and well managed.

本文链接: https://brand.waitui.com/52bc17e3b.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

美股大型科技股盘前多数上涨,Meta涨0.9%

36氪获悉,美股大型科技股盘前多数上涨,截至发稿,Meta涨0.9%,英伟达涨0.72%,微软涨0.24%,亚马逊涨0.21%,特斯拉涨0.15%,奈飞涨0.1%;苹果跌0.19%,谷歌跌0.14%。

2小时前

热门中概股美股盘前多数下跌,新东方跌超10%

36氪获悉,热门中概股美股盘前多数下跌,截至发稿,新东方跌超10%,蔚来、小鹏汽车跌超2%,理想汽车、富途控股跌超1%;名创优品涨超1%,百度涨0.29%。

2小时前

特朗普:第二季度GDP数据远好于预期

据外媒报道,特朗普表示,第二季度GDP数据刚刚公布,远好于预期。(第一财经)

2小时前

普拉达上半年净营收27.4亿欧元,同比增加8%

普拉达7月30日公布2025年上半年财报显示,净营收27.4亿欧元,同比增加8%,净利润3.86亿欧元。(界面)

2小时前

三星医疗:子公司中标2955.5万美元美国Nexgrid智能电表框架项目

36氪获悉,三星医疗发布公告,公司下属控股墨西哥子公司南森墨西哥中标美国Nexgrid智能电表框架项目,合同金额总计2955.5万美元,约合2.12亿人民币,占公司2024年度经审计营业收入的1.45%。

2小时前

本页详细列出关于朗迪Reneed的品牌信息,含品牌所属公司介绍,朗迪Reneed所处行业的品牌地位及优势。
咨询